ProteinLogic has developed a novel technology platform (ImmiPrint®) focused on the diagnosis of tuberculosis (TB). Along with HIV/AIDS, TB is the most significant infectious disease worldwide. Early and accurate diagnosis is essential for its control. The ImmiPrint® platform has the potential to deliver an effective blood-based TB diagnostic, and to provide information on disease progression. The test may also be able to predict which individuals are likely to respond to anti-microbial therapy.
Looking for a particular ProteinLogic Ltd employee's phone or email?
The ProteinLogic Ltd annual revenue was $4 million in 2026.
The NAICS codes for ProteinLogic Ltd are [541713, 541, 5417, 54171, 54].
The SIC codes for ProteinLogic Ltd are [87, 873].